Skip to Content
MilliporeSigma

Key Documents

View All Documentation

Skip To

SML2263

Ladostigil tartrate

≥98% (HPLC)

Synonym(s):

(3R)-(N-Propargylaminoindan-5-yl)-ethyl methyl carbamate tartrate (2:1), TV-3326, TV3326

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
5 mg

Available to ship TODAYfromMILWAUKEE

$90.30
$76.75
25 mg

Available to ship TODAYfromMILWAUKEE

$363.00
$308.55

About This Item

Empirical Formula (Hill Notation):
C16H20N2O2 · 0.5C4H6O6
CAS Number:
209394-46-7
Molecular Weight:
347.39
UNSPSC Code:
12352200
MDL number:
MFCD22741393
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

$76.75

List Price$90.30Save 15%
Web-Only Promotion

Available to ship TODAYDetails

​
Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

N([C@@H]3CCc4c3cc(cc4)OC(=O)N(CC)C)CC#C.N([C@@H]1CCc2c1cc(cc2)OC(=O)N(CC)C)CC#C.O[C@H]([C@@H](O)C(=O)O)C(=O)O

InChI

1S/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1

InChI key

PRLVBVAJMQZMJN-OGOSNNLPSA-N

Biochem/physiol Actions

Ladostigil, a carbamate is also a butyryl cholinesterase (BuChE) inhibitor.[1] It possesses anti-inflammatory property and effectively reduces the levels of tumor necrosis factor α (TNF-α) in lipopolysaccharide (LPS)-activated macrophages.[1] It provides protection to cardiomyocytes.[2] Ladostigil has neuroprotective functionality and has the potential to treat mild cognitive impairment (MCI) and spatial memory deficits development.[3] It also exhibits protective effects during oxidative and nitrative stress.[3]
Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.
Multifunctional drug designed to treat Alzhemier′s disease by combining in a single molecule the neuroprotective/neurorestorative effects of the (MAO)-B inhibitor rasagiline with the cholinesterase (ChE) inhibitory activity of rivastigmine.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML2351SML0881M5449
Ladostigil tartrate ≥98% (HPLC)

Sigma-Aldrich

SML2263

Ladostigil tartrate

Dabigatran etexilate ≥98% (HPLC)

Sigma-Aldrich

SML2351

Dabigatran etexilate

Rivastigmine tartrate ≥98% (HPLC)

Sigma-Aldrich

SML0881

Rivastigmine tartrate

MKT-077 ≥98% (HPLC), powder

Sigma-Aldrich

M5449

MKT-077

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

-

solubility

H2O: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

H2O: 15 mg/mL, clear

solubility

H2O: 10 mg/mL, clear

color

white to beige

color

white to beige

color

white to beige

color

orange to red

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000185162
0000185160
0000167599
0000185162
0000185160

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rony Panarsky et al.
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 7(2), 488-498 (2012-03-29)
Impaired mitochondrial function accompanied by microglial activation and the release of nitric oxide (NO) and pro-inflammatory cytokines has been reported in Alzheimer's disease, its prodromal phase of Mild Cognitive Impairment (MCI) and in aged rats. The present study showed that
John P M Finberg et al.
Frontiers in pharmacology, 7, 340-340 (2016-11-03)
Inhibitors of MAO-A and MAO-B are in clinical use for the treatment of psychiatric and neurological disorders respectively. Elucidation of the molecular structure of the active sites of the enzymes has enabled a precise determination of the way in which
Orly Weinreb et al.
British journal of pharmacology, 173(13), 2080-2094 (2015-09-04)
Alzheimer's disease (AD) is accepted nowadays as a complex neurodegenerative disorder with multifaceted cerebral pathologies, including extracellular deposition of amyloid β peptide-containing plaques, intracellular neurofibrillary tangles, progressive loss of cholinergic neurons, metal dyshomeostasis, mitochondrial dysfunction, neuroinflammation, glutamate excitoxicity, oxidative stress
View All Related Papers

Global Trade Item Number

SKUGTIN
SML2263-25MG04061835504954
SML2263-5MG04061835504961

Questions

Reviews

No rating value

Active Filters